A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

NCT07449234 · clinicaltrials.gov ↗
RECRUITING
Status
200
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Janssen-Cilag Ltd.